US FDA approves isatuximab for relapsed refractory multiple myeloma

The U.S. FDA has approved isatuximab in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

Source:

US Food and Drug Administration